Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-11-27
2010-11-02
Pryor, Alton N (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07825113
ABSTRACT:
The use of a compound comprising formula (I):or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them.In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.
REFERENCES:
patent: 4657893 (1987-04-01), Krantz et al.
patent: 4665070 (1987-05-01), Krantz et al.
patent: 4745116 (1988-05-01), Krantz et al.
patent: 5776756 (1998-07-01), Kimura et al.
patent: 6624161 (2003-09-01), Hodson et al.
patent: 246 996 (1987-06-01), None
patent: 246996 (1987-06-01), None
patent: 0206323 (1986-12-01), None
patent: WO96/07648 (1996-03-01), None
patent: WO99/16758 (1999-04-01), None
Hays et al. “2-Amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r Serine Protease”J. Med Chem. 1998, 41, 1060-1067.
Krantz et al. “Design and Synthesis of 4H-3,1-Benzoxazin-4-ones as Potent Alternative Substrate Inhibitors of Human Leukocyte Elastase”J. Med Chem. 1990, 33, 464-479.
Krantz et al. “Design of Alternate Substrate Inhibitors of Serine Proteases. Synergistic Use of Alkyl Substitution to Impede Enzyme-Catalyzed Deacvlation”J. Med. Chem. 1987, 30 (4), 589-590.
Krantz et al. “Design of Alternate Substrate Inhibitors of Serine Proteases: Tactics for Obstructing Deacylation Pathways”Advances in Biosciences1987. 65. 213-220.
Neumann et al. “Inhibition of Chymotrypsin and Pancreatic Elastase by 4H-3,1-Benzoxazin-4-ones”J. Enzvme Inhibition, 1991, 4, 227-232.
Gutschow et al. “Inhibition of Cathepsin G by 4H-3,1-Benzoxazin-4-ones”Bioorg. Med. Chem. 1997, 5, 1935-1942.
Jarvest et al. “Inhibition of HSV-1 Protease by Benzoxazinones”Bioorg. Med. Chem.1996, 6, 2463-2466.
PCT/GB00/00032; International Search Report mailed Dec. 12, 2000.
Carr Beverley Jane
Downham Robert
Dunk Christopher Robert
Hodson Harold Francis
Mitchell Timothy John
Choate Hall & Stewart LLP
Lyon Charles E.
Norgine B.V.
Pryor Alton N
Rearick John P.
LandOfFree
2-oxy-benzoxazinone derivatives for the treatment of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-oxy-benzoxazinone derivatives for the treatment of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-oxy-benzoxazinone derivatives for the treatment of obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183171